Shots:

• AstraZeneca to get exclusive promotion rights for toripalimab in mainland China for the urothelial carcinoma indications and all indications in non-core areas
• Junshi will continue responsible for the promotion of other approved indications and to be approved excluding urothelial carcinoma in core areas
• The companies will continue to explore overseas business collaborations including emerging markets and actively explore the possibility of expanding the future collaborations

 ­ Ref: GlobeNewswire | Image: New Europe